Arthritis & Rheumatism, Volume 63,
November 2011 Abstract Supplement

Abstracts of the American College of
Rheumatology/Association of Rheumatology Health Professionals
Annual Scientific Meeting
Chicago, Illinois November 4-9, 2011.


Safety of Infliximab Therapy in Rheumatoid Arthritis Patients with Pre-Existing Hepatitis B Virus Infection.

Zhang1,  Xuewu, Liu2,  Xia, An1,  Yuan, Ning1,  Ying, Li1,  Zhanguo

Peking University People's Hospital, Beijing, China
China-Japan Friendship Hospital, Beijing, China

Background/Purpose:

To evaluate the safety of treatment with tumor necrosis factor-a (TNF-a) monoclonal antibody (Infliximab) in patients with rheumatoid arthritis(RA) who had normal liver function and pre-existent HBV infection.

Methods:

In this multicenter study, all 41 cases met the ACR 1987 revised criteria for RA, including 7 men and 34 women, with average age of 46.2±2.72 years old and average disease course of 11.40±5.72 years. Upon enrollment, patients were assessed for HBsAg, anti-HBC, anti-HbsAb, anti-HBeAb. All patients were HBsAg(-); four of them were only anti-HBC (+); fifteen were anti-HBsAb (+), anti-HBeAb (+) and anti-HBc (+); six were anti-HBsAb (+) and anti-HBeAb (+); forteen were anti-HBsAb(+) and anti-HBc(+), two were anti-HBeAb (+) and anti-HBc (+). 40 patients had normal ALT and AST, and one patient with positive anti-HBc showed elevated ALT before administration of infliximab (60U/L). All patients received intravenous Infliximab therapy with dose of 3 mg/kg at week 0, 2, 6, 14 and 22 respectively after testing liver enzyme, Creatinine, T-bilirubin, leukocyte and platelet. All the above five parameters and HBsAg were reexamined at week 26.

Results:

40 out of 41 patients have their ALT, AST, T-bilirubin, Creatinine, leukocyte and platelet within normal range, with no significant difference between HBV positive and HBV negative groups. As for the patients with elevated ALT and AST levels after infliximab infusion, there was no statistically significant difference between previously HBV infected patients and patients without history of HBV infection. All patients reexamined for HBsAg at week 26 showed negative results.

Conclusion:

In RA patients with pre-existing HBV infections, liver function abnormality were not observed during the Infliximab administration, as long as HBsAg was negative with normal liver function at baseline.

To cite this abstract, please use the following information:
Zhang, Xuewu, Liu, Xia, An, Yuan, Ning, Ying, Li, Zhanguo; Safety of Infliximab Therapy in Rheumatoid Arthritis Patients with Pre-Existing Hepatitis B Virus Infection. [abstract]. Arthritis Rheum 2011;63 Suppl 10 :2526
DOI:

Abstract Supplement

Meeting Menu

2011 ACR/ARHP